RBC Capital analyst Daniel Perlin raised the firm’s price target on Global Payments (GPN) to $139 from $130 and keeps an Outperform rating on ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...

Medically reviewed by Gagandeep Brar, MD Bone marrow is the deep, interior portion of your bone. Your bone marrow, which has ...

Russian forces struck the sarcophagus of the Chornobyl nuclear power plant (NPP) overnight on February 14, causing damage.

The prospect of a growing trade war isn’t just a risk to Canada’s industries, it also poses a threat to the Canadian housing market, says RBC Economics.

Following the company’s second quarter results, RBC analyst Drew McReynolds has raised his price target on WildBrain.

Changes associated with anemia tongue are called glossitis, otherwise known as tongue inflammation. This article explains why ...

CEO Eric Steigerwalt highlighted 2024 as a year of both achievements and challenges. He emphasized the company's progress on strategic initiatives aimed at improving capital efficiency and maintaining ...

The recently integrated tool was recognized by the Business Intelligence Group with a 2025 BIG Innovation Award. The launch ...

Brighthouse Financial, Inc. ( NASDAQ: BHF) Q4 2024 Results Conference Call February 12, 2025 8:00 AM ET ...

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...